Monotherapy, treatment adherence and satisfaction of schizophrenic patients are essential for good prognosis and disease evolution. The use of depot treatments such as paliperidone palmitate, could be the beginning to get all these objectives in the treatment of all of our patients.

To measure in a pool of schizophrenic patients starting treatment with paliperidone palmitate, the time they take to re-enter as in-patients, if monotherapy is get and the degree of satisfaction of these patients regarding treatment is achieved.

A pool of schizophrenic patients discharged from our Short-Term Hospitalization Unit between October 2014 and February 2015 with introduction into its paliperidone palmitate treatment.

waiting to be achieved

and in the results of similar studies, we think that paliperidone palmitate is a drug of choice in many schizophrenic patients who can benefit from their use to be well tolerated, to control the disease by reducing the number of readmissions, improve the therapeutic adherence, patient satisfaction with their treatment and to get a treatment with a single antipsychotic.